Thromboprophylaxis in patients undergoing hemodialysis

Cover Page

Cite item

Full Text

Abstract

The review presents an analysis of the results of the use of different anticoagulants for the prevention of thrombosis in patients with terminal stage of chronic kidney disease on regular hemodialysis (HD). A better safety profile for hypersensitivity and risk of bleeding noted in low-molecular-weight heparin compared with unfractionated heparin. The indications and methods of blood anticoagulation using unfractionated and low-molecular heparin, as well as sodium citrate, possible complications in their use and methods of correction of possible complications are described. The article contains recommendations on the use of low molecular weight heparinoids and prostacyclin to prevent blood clots in patients undergoing HD with a high risk of bleeding and intolerance to heparin and trisodium citrate. The article is intended for nephrologists, specialists in extracorporeal methods of treatment (hemodialysis, haemofiltration, hemodiafiltration).

About the authors

Yu. S Milovanov

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф. каф. внутренних, профессиональных болезней и пульмонологии 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

I. A Dobrosmyslov

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

врач-нефролог, зав. отд-нием «Искусственная почка» Университетской клинической больницы №3 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

S. Yu Milovanova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: yuriymilovanov@mail.ru
д-р мед. наук, вед. науч. сотр. научно-исследовательского отд. здоровьесберегающих технологий Научно-технологического парка биомедицины 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Бикбов Б.Т., Томилина Н.А. Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998-2011 гг. (Отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ. 2014; 16 (1): 3-12.
  2. Готье С.В., Мойсюк Я.Г., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации. VI сообщение регистра Российского трансплантологического общества. Вестн. трансплантологии и искусственных органов. 2014; 16 (2): 3-9
  3. National Kidney Foundation KDOQI Clinical Practice Guidelines for Vascular Access, Update 2006.
  4. Николаев А.Ю., Милованов Ю.С. Лечение почечной недостаточности. Руководство для врачей. 2-е изд. М.: МИА, 2011.
  5. National Kidney Foundation KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients 2005.
  6. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 3 (1).
  7. European Best Practice Guidelines for Haemodialysis (Part 1). Nephrol Dial Transplant 2002; 17 (Suppl. 7).
  8. European best practice guidelines on haemodialysis (Part 2). Nephrol Dial Transplant 2007; 22 (Suppl. 2).
  9. National Kidney Foundation KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006.
  10. Davenport A. Optimization of heparin anticoagulation for hemodialysis. Hemodial Int 2011; 15 (Suppl. 1): 43-8.
  11. Fischer K.G. Essentials of anticoagulation in hemodialysis. Hemodial Int 2007; 11: 178-89.
  12. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Supplements 2012; 2 (4).
  13. Daugirdas J.T. Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther 1995; 2 (4): 295-304.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies